Fortuna Mining Corp. Common Shares vs TransMedics Group Inc — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.85 (market cap $3.13B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Fortuna Mining Corp. Common Shares and TransMedics Group Inc are close in size by market cap, and Fortuna Mining Corp. Common Shares is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 0 Days and TransMedics Group Inc for 24 Days on average.
| FSM | TMDX | |
|---|---|---|
Market Cap | $3.13B | $2.74B |
Volume | 6,504,680 | 949,331 |
Sector | Basic Materials | Health |
52-Week High | $13.66 | $150.42 |
52-Week Low | $7.84 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $2.75B | $3.13B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →